BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 29220291)

  • 1. Emerging Targeted and Immune-Based Therapies in Sarcoma.
    Pollack SM; Ingham M; Spraker MB; Schwartz GK
    J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
    Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
    Front Immunol; 2021; 12():775761. PubMed ID: 34925348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of immunotherapy for sarcomas.
    Miwa S; Nishida H; Tsuchiya H
    Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next frontiers in systemic therapy for soft tissue sarcoma.
    Yen CC; Chen TW
    Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
    Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
    Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic approaches to sarcoma.
    Burgess M; Tawbi H
    Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
    Toulmonde M; Penel N; Adam J; Chevreau C; Blay JY; Le Cesne A; Bompas E; Piperno-Neumann S; Cousin S; Grellety T; Ryckewaert T; Bessede A; Ghiringhelli F; Pulido M; Italiano A
    JAMA Oncol; 2018 Jan; 4(1):93-97. PubMed ID: 28662235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Sarcoma: Future Horizons.
    Burgess M; Gorantla V; Weiss K; Tawbi H
    Curr Oncol Rep; 2015 Nov; 17(11):52. PubMed ID: 26423769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
    Martín-Broto J; Moura DS; Van Tine BA
    Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Trends in Immunotherapy for Adult Sarcomas.
    Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
    Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
    Wisdom AJ; Mowery YM; Riedel RF; Kirsch DG
    Cancer; 2018 Oct; 124(19):3819-3829. PubMed ID: 29723407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
    Zhu MMT; Shenasa E; Nielsen TO
    Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Therapy for Sarcomas.
    Anderson PM
    Adv Exp Med Biol; 2017; 995():127-140. PubMed ID: 28321815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Virus-Directed Therapy in Soft Tissue Sarcoma.
    Chaudhary H; D'Angelo S
    Curr Treat Options Oncol; 2022 Mar; 23(3):404-414. PubMed ID: 35258792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From vision to reality: deploying the immune system for treatment of sarcoma.
    Wilky BA; Goldberg JM
    Discov Med; 2017 Jan; 23(124):61-74. PubMed ID: 28245428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
    Banks LB; D'Angelo SP
    J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.